 Godela Brosnahan
Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 25 | 2022 | 209 | 5.250 |
Why?
| | Kidney | 17 | 2022 | 1351 | 1.790 |
Why?
| | Glomerular Filtration Rate | 15 | 2022 | 681 | 1.550 |
Why?
| | Kidney Failure, Chronic | 6 | 2020 | 514 | 1.460 |
Why?
| | Disease Progression | 16 | 2022 | 2477 | 1.190 |
Why?
| | Renal Insufficiency, Chronic | 5 | 2020 | 586 | 1.060 |
Why?
| | Hypertension | 8 | 2018 | 1199 | 0.850 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 6 | 2018 | 194 | 0.830 |
Why?
| | Antihypertensive Agents | 5 | 2018 | 436 | 0.760 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2018 | 84 | 0.640 |
Why?
| | Renin-Angiotensin System | 2 | 2018 | 82 | 0.640 |
Why?
| | Metformin | 1 | 2021 | 293 | 0.620 |
Why?
| | Uric Acid | 1 | 2021 | 349 | 0.610 |
Why?
| | Benzoates | 3 | 2014 | 40 | 0.580 |
Why?
| | Blood Pressure | 8 | 2018 | 1656 | 0.540 |
Why?
| | TRPP Cation Channels | 5 | 2020 | 63 | 0.500 |
Why?
| | Nephrology | 1 | 2014 | 50 | 0.460 |
Why?
| | Specialization | 1 | 2014 | 119 | 0.440 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 387 | 0.430 |
Why?
| | Middle Aged | 21 | 2021 | 27511 | 0.340 |
Why?
| | Polymyalgia Rheumatica | 1 | 2008 | 2 | 0.340 |
Why?
| | Iron Chelating Agents | 1 | 2008 | 16 | 0.330 |
Why?
| | Nephritis, Interstitial | 1 | 2008 | 15 | 0.330 |
Why?
| | Triazoles | 1 | 2008 | 128 | 0.300 |
Why?
| | Adult | 21 | 2021 | 31325 | 0.300 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 990 | 0.280 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1183 | 0.260 |
Why?
| | Physicians | 1 | 2014 | 792 | 0.260 |
Why?
| | Mutation | 5 | 2020 | 3435 | 0.250 |
Why?
| | Lisinopril | 2 | 2014 | 14 | 0.250 |
Why?
| | Creatinine | 4 | 2018 | 491 | 0.240 |
Why?
| | Male | 23 | 2022 | 57476 | 0.230 |
Why?
| | Benzimidazoles | 2 | 2014 | 139 | 0.230 |
Why?
| | Humans | 31 | 2022 | 118257 | 0.230 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2018 | 1237 | 0.230 |
Why?
| | Young Adult | 9 | 2020 | 10731 | 0.230 |
Why?
| | Female | 23 | 2022 | 61262 | 0.220 |
Why?
| | Prospective Studies | 6 | 2022 | 6443 | 0.210 |
Why?
| | Kidney Transplantation | 1 | 2008 | 576 | 0.210 |
Why?
| | Risk Assessment | 3 | 2020 | 3043 | 0.180 |
Why?
| | Time Factors | 4 | 2018 | 6368 | 0.180 |
Why?
| | Adolescent | 8 | 2018 | 18364 | 0.170 |
Why?
| | Treatment Outcome | 4 | 2018 | 9319 | 0.170 |
Why?
| | Feasibility Studies | 1 | 2021 | 746 | 0.160 |
Why?
| | Age Factors | 2 | 2018 | 2990 | 0.160 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 2 | 2014 | 32 | 0.160 |
Why?
| | Evidence-Based Medicine | 2 | 2014 | 690 | 0.150 |
Why?
| | Medical History Taking | 1 | 2017 | 120 | 0.150 |
Why?
| | Kidney Function Tests | 1 | 2018 | 163 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2018 | 137 | 0.150 |
Why?
| | Enalapril | 3 | 2002 | 18 | 0.140 |
Why?
| | Diet, Sodium-Restricted | 1 | 2016 | 34 | 0.140 |
Why?
| | Sodium Chloride, Dietary | 1 | 2016 | 49 | 0.140 |
Why?
| | Bayes Theorem | 1 | 2018 | 341 | 0.140 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 709 | 0.140 |
Why?
| | Risk Factors | 3 | 2017 | 8958 | 0.140 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 252 | 0.140 |
Why?
| | Longitudinal Studies | 3 | 2018 | 2491 | 0.130 |
Why?
| | Hepatomegaly | 1 | 2014 | 2 | 0.130 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 5 | 0.120 |
Why?
| | Endothelium | 1 | 2014 | 116 | 0.120 |
Why?
| | Organ Size | 3 | 2020 | 460 | 0.110 |
Why?
| | Sex Factors | 1 | 2018 | 1765 | 0.110 |
Why?
| | Amlodipine | 2 | 2002 | 8 | 0.100 |
Why?
| | Proteinuria | 2 | 2010 | 99 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2413 | 0.100 |
Why?
| | Perception | 1 | 2014 | 314 | 0.100 |
Why?
| | Genotype | 4 | 2020 | 1870 | 0.100 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2010 | 11 | 0.090 |
Why?
| | Hyperphosphatemia | 1 | 2010 | 14 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2659 | 0.090 |
Why?
| | Prognosis | 1 | 2018 | 3424 | 0.090 |
Why?
| | Acidosis | 1 | 2010 | 84 | 0.080 |
Why?
| | Comorbidity | 1 | 2014 | 1516 | 0.080 |
Why?
| | Iron Overload | 1 | 2008 | 10 | 0.080 |
Why?
| | Anemia | 1 | 2010 | 145 | 0.080 |
Why?
| | Oxidative Stress | 1 | 2014 | 1167 | 0.080 |
Why?
| | Prednisone | 1 | 2008 | 235 | 0.080 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2007 | 16 | 0.080 |
Why?
| | Drug Hypersensitivity | 1 | 2008 | 85 | 0.070 |
Why?
| | Myelodysplastic Syndromes | 1 | 2008 | 118 | 0.070 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 182 | 0.070 |
Why?
| | Eosinophils | 1 | 2008 | 282 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2014 | 1433 | 0.070 |
Why?
| | Acute Disease | 1 | 2008 | 933 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1197 | 0.060 |
Why?
| | Obesity | 1 | 2017 | 2715 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 3 | 2022 | 3169 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1379 | 0.060 |
Why?
| | Glucocorticoids | 1 | 2008 | 545 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2007 | 377 | 0.060 |
Why?
| | Prevalence | 1 | 2010 | 2321 | 0.060 |
Why?
| | Hypertrophy, Left Ventricular | 2 | 2002 | 107 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1857 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2014 | 964 | 0.050 |
Why?
| | Cysts | 1 | 2022 | 93 | 0.050 |
Why?
| | Liver | 2 | 2022 | 1803 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2014 | 1683 | 0.050 |
Why?
| | Calcium Channel Blockers | 1 | 2000 | 114 | 0.040 |
Why?
| | Body Height | 1 | 2020 | 186 | 0.040 |
Why?
| | Liver Diseases | 1 | 2022 | 282 | 0.040 |
Why?
| | ROC Curve | 1 | 2020 | 470 | 0.040 |
Why?
| | Heart | 1 | 2002 | 630 | 0.040 |
Why?
| | Albuminuria | 2 | 2014 | 196 | 0.040 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2000 | 287 | 0.040 |
Why?
| | Renal Elimination | 1 | 2016 | 6 | 0.040 |
Why?
| | Natriuresis | 1 | 2016 | 14 | 0.040 |
Why?
| | Gene Expression | 1 | 2000 | 1482 | 0.030 |
Why?
| | Aldosterone | 1 | 2014 | 43 | 0.030 |
Why?
| | Proteins | 1 | 2000 | 935 | 0.030 |
Why?
| | Prostaglandins | 1 | 2014 | 78 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2000 | 1048 | 0.030 |
Why?
| | Liver Function Tests | 1 | 2014 | 107 | 0.030 |
Why?
| | Forecasting | 1 | 2016 | 348 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 13 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 16 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2016 | 355 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2433 | 0.030 |
Why?
| | Overweight | 1 | 2017 | 492 | 0.030 |
Why?
| | United States | 1 | 2010 | 12491 | 0.030 |
Why?
| | Phenotype | 2 | 2016 | 2937 | 0.030 |
Why?
| | Cystic Fibrosis | 1 | 2000 | 963 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5078 | 0.020 |
Why?
| | Body Mass Index | 1 | 2017 | 2074 | 0.020 |
Why?
| | Aged | 3 | 2020 | 19594 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2014 | 891 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4574 | 0.020 |
Why?
| | Child | 1 | 2006 | 19033 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 4522 | 0.010 |
Why?
| | Inflammation | 1 | 2014 | 2545 | 0.010 |
Why?
| | Signal Transduction | 1 | 2014 | 4688 | 0.010 |
Why?
| | Echocardiography | 1 | 2002 | 556 | 0.010 |
Why?
| | Pedigree | 1 | 2000 | 485 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2000 | 1681 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2007 | 12929 | 0.010 |
Why?
|
|
Brosnahan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|